Lack of Effect on Hypothalamic-Pituitary-Adrenal (HPA) Axis Function by Once-daily Fluticasone Furoate∗ Nasal Spray (FFNS) 110 mcg in Children with Perennial Allergic Rhinitis (PAR) ∗USAN approved name

Tripathy, Ita; Sterling, Rosalyn P.; Clements, Diane; Wu, Wei; Faris, Melissa; Philpot, E.

doi:10.1016/j.jaci.2006.12.277

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FF displayed high selectivity for the glucocorticoid receptor in vitro and had no effect on the hypothalamic-pituitary-adrenal (HPA) axis in children or adults during clinical trials (Pastel et al 2007; Salter et al 2007; Tripathy et al 2007). Laboratory tests that assess basal and dynamic function of HPA axis are frequently used to determine the systemic effects of INS.…”

Section: Fluticasone Furoatementioning

confidence: 99%

Fluticasone furoate nasal spray in the treatment of allergic rhinitis

Giavina‐Bianchi¹

2008

TCRM

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a prevalent disease with great morbidity and signifi cant societal and economic burden. Intranasal corticosteroids are recommended as fi rst-line therapy for patients with moderate-to-severe disease, especially when nasal congestion is a major component of symptoms. To compare the effi cacy and safety profi le of different available intranasal corticosteroids for the treatment of AR, it is important to understand their different structures and pharmacokinetic and pharmacodynamic properties. Knowledge of these drugs has increased tremendously over the last decade. Studies have elucidated mechanisms of action, pharmacologic properties, and the clinical impact of these drugs in allergic respiratory diseases. Although the existing intranasal corticosteroids are already highly effi cient, the introduction of further improved formulations with a better effi cacy/ safety profi le is always desired. Fluticasone furoate nasal spray is a new topical corticosteroid, with enhanced-affi nity and a unique side-actuated delivery device. As it has high topical potency and low potential for systemic effects, it is a good candidate for rhinitis treatment.

show abstract

Section: Fluticasone Furoatementioning

confidence: 99%

Fluticasone furoate nasal spray in the treatment of allergic rhinitis

Giavina‐Bianchi¹

2008

TCRM

View full text Add to dashboard Cite

show abstract

“…The ratios (95% confidence interval) for FF 50, 100, 200, 400, and 800 micrograms were 1.00 (0.89-1.13), 1.04 (0.94-1.16), 1.05 (0.96-1.14), 1.06 (0.95-1.19), and 0.92 (0.82-1.04), respectively. Tripathy and colleagues measured serum cortisol levels after 6 weeks of therapy with FF in children aged 2 to 12 years with perennial AR [ 18 ]. The ratio of end of treatment to baseline was 0.98 in the placebo group and 0.94 in the FF-treated group.…”

Section: Hpa Axismentioning

confidence: 99%

Evaluating the Safety of Intranasal Steroids in the Treatment of Allergic Rhinitis

Sheth

2008

All Asth Clin Immun

View full text Add to dashboard Cite

Given that intranasal corticosteroids (INCs) are widely considered first-line therapies for treatment of rhinitis, it is important for the clinician to be comfortable with the side-effect profile and be able to discuss potential safety concerns regarding these therapies. Among the safety concerns with the use of INCs are the potential for growth suppression both short and long term, the potential for hypothalamic-pituitary-adrenal axis suppression, ocular safety, and the use of INCs concomitantly with inhaled corticosteroids in asthma patients. As all clinicians are aware, each patient can have individual responses to both efficacy and safety; however, the data reviewed suggest that the benefits outweigh the potential risks. Understanding the potential concerns and the data behind these concerns should give clinicians the information to be able to discuss this with patients and parents to incorporate appropriate therapy for those with allergic rhinitis

show abstract

Safety of intranasal corticosteroids

Bensch¹

2016

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Lack of Effect on Hypothalamic-Pituitary-Adrenal (HPA) Axis Function by Once-daily Fluticasone Furoate∗ Nasal Spray (FFNS) 110 mcg in Children with Perennial Allergic Rhinitis (PAR) ∗USAN approved name

Cited by 4 publications

References 0 publications

Fluticasone furoate nasal spray in the treatment of allergic rhinitis

Fluticasone furoate nasal spray in the treatment of allergic rhinitis

Evaluating the Safety of Intranasal Steroids in the Treatment of Allergic Rhinitis

Safety of intranasal corticosteroids

Contact Info

Product

Resources

About